ImageneBio (NASDAQ:IMA) Trading Up 0.5% – Should You Buy?

ImageneBio, Inc. (NASDAQ:IMA)’s stock price shot up 0.5% during trading on Wednesday . The stock traded as high as $7.40 and last traded at $7.39. 30,752 shares were traded during trading, an increase of 30% from the average session volume of 23,604 shares. The stock had previously closed at $7.35.

Analysts Set New Price Targets

Several research analysts have recently issued reports on IMA shares. Wall Street Zen downgraded shares of ImageneBio from a “hold” rating to a “strong sell” rating in a report on Saturday, November 15th. Leerink Partners began coverage on ImageneBio in a research report on Friday, October 24th. They set an “outperform” rating and a $30.00 target price on the stock. Weiss Ratings initiated coverage on ImageneBio in a research note on Wednesday, October 22nd. They set a “sell (e-)” rating on the stock. Finally, Wedbush downgraded ImageneBio from a “neutral” rating to an “underperform” rating in a research report on Tuesday, November 25th. One research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, ImageneBio has an average rating of “Hold” and a consensus target price of $26.50.

ImageneBio Stock Performance

The firm has a market capitalization of $82.62 million, a price-to-earnings ratio of -0.92 and a beta of 0.43. The firm’s 50-day moving average price is $6.64 and its two-hundred day moving average price is $9.54.

ImageneBio (NASDAQ:IMA) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($2.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.47) by ($1.44). As a group, equities research analysts anticipate that ImageneBio, Inc. will post -0.91 EPS for the current year.

Insider Activity at ImageneBio

In related news, Director Joseph P. Slattery purchased 16,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 24th. The shares were acquired at an average price of $5.99 per share, with a total value of $95,840.00. Following the purchase, the director directly owned 16,000 shares in the company, valued at $95,840. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 5.94% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of IMA. Deep Track Capital LP bought a new stake in ImageneBio during the 3rd quarter worth approximately $7,160,000. Blue Owl Capital Holdings LP bought a new position in ImageneBio in the 3rd quarter valued at $4,409,000. Atlas Venture Life Science Advisors LLC acquired a new position in ImageneBio in the third quarter worth $3,079,000. Vanguard Group Inc. bought a new stake in shares of ImageneBio during the third quarter worth $1,902,000. Finally, BML Capital Management LLC bought a new stake in shares of ImageneBio during the third quarter worth $1,487,000. 75.00% of the stock is currently owned by institutional investors and hedge funds.

ImageneBio Company Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.